LLY Jul 2024 880.000 call
| Previous close | 12.95 |
| Open | 14.40 |
| Bid | 19.00 |
| Ask | 20.45 |
| Strike | 880.00 |
| Expiry date | 2024-07-19 |
| Day's range | 14.40 - 21.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 667 |
- Yahoo Finance Video
Can GLP-1 weight-loss drug manufacturers keep momentum up?
As GLP-1 weight-loss drugs have boosted several healthcare stocks, Jennison Associates Head of Global Equity Mark Baribeau joins Market Domination Overtime to discuss whether these companies can keep up the momentum. Baribeau points to Novo Nordisk (NVO) and Eli Lilly (LLY) as companies seeing major revenue growth and likely to split the market. He sees weight-loss and type 2 diabetes drugs as a "paradigm shift" that present huge opportunities for both companies. However, he notes that while consumer demand for these drugs is skyrocketing, Novo Nordisk and Eli Lilly "don't have the manufacturing capacity to keep up with demand. So the gating factor here is really supply. It's not demand." He adds that as manufacturing capacities expand, growth will accelerate, making the industry's backdrop look "very, very healthy." For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Melanie Riehl
ZacksPharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
Investor's Business DailyMagnificent Seven? Just Two Members Clear This Bar
Ultimately, earnings drive share prices. Only two Magnificent Seven stocks, and a third megacap, meet this triple-25% growth standard.
